Humalog pen (insulin lispro) / Eli Lilly - LARVOL DELTA

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia (clinicaltrials.gov) - P=N/A | N=20 | Active, not recruiting | Sponsor: Centre for Addiction and Mental Health | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2026 ➔ Dec 2026 | Trial primary completion date: Aug 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Metabolic Disorders • Psychiatry • Schizophrenia

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=85 | Terminated | Sponsor: Emory University | N=255 ➔ 85 | Active, not recruiting ➔ Terminated; The study was suspended and during this time recruitment and study activities were halted. The study was ultimately terminated in April 2026 without having re-opened for recruitment additional participants.

Enrollment change • Trial termination • Diabetes • Metabolic Disorders

SPEED: Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Stanford University | Recruiting ➔ Completed | N=20 ➔ 10 | Trial completion date: Oct 2026 ➔ May 2026

Enrollment change • Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

When Cancer Immunotherapy Tips the Balance: Pembrolizumab-Induced Type 1 Diabetes (ENDO 2026) - "After discharge, the patient remained insulin dependent.By 2025, she was managed with basal insulin degludec (Tresiba) and carbohydrate-based prandial insulin lispro (Humalog). 95.3% of patients remain insulin-dependent long-term, and only 2% are eventually able to discontinue insulin therapy.The National Comprehensive Cancer Network recommends obtaining a comprehensive metabolic panel before each treatment with follow-up HbA1c testing if hyperglycemia is detected. Any new onset of hyperglycemia in a patient receiving pembrolizumab should be considered potential immune-mediated diabetes until an alternative diagnosis is confirmed."

Acute Kidney Injury • Diabetes • Esophageal Adenocarcinoma • Heart Failure • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Solid Tumor • Type 1 Diabetes Mellitus

Using CGM to Describe Dietary Glucose (G)/Insulin (I) Responses (ADA 2026) - "Ta = 35 minutes; I = 8 units Humalog; Tb = 305 minutes... This pharmacokinetic analysis provides another way to describe glucose disposal in individuals with diabetes. It directly analyzes the CGM meal related glucose excursions based on dietary information. It demonstrates the difficulty of achieving normal A1c and glucose excursions of less than 120 minutes duration using pre-meal insulin in persons with diabetes."

Diabetes • Metabolic Disorders

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Centre for Addiction and Mental Health | Trial completion date: Apr 2026 ➔ Aug 2026 | Trial primary completion date: Apr 2026 ➔ Aug 2026

Trial completion date • Trial primary completion date • CNS Disorders • Metabolic Disorders • Psychiatry • Schizophrenia

KKB_2023_FActIn-T1DM: Fast-Acting Insulins and Their Post-Meal Effects in Type 1 Diabetes (clinicaltrialsregister.eu) - P1 | N=20 | Completed | Sponsor: Katholisches Klinikum Bochum gGmbH | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents (clinicaltrials.gov) - P=N/A | N=24 | Completed | Sponsor: Centre for Addiction and Mental Health | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Ultrarapid Lispro (Lyumjev) Has an Improved Pharmacokinetic Profile for Exercise Compared With Humalog, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. (PubMed, Diabetes Care) - "Using Lyumjev in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with Humalog, with fewer hypoglycemic events in active adults with type 1 diabetes."

Journal • PK/PD data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=11 | Completed | Sponsor: Mark D. DeBoer, MD, MSc., MCR | Recruiting ➔ Completed | N=20 ➔ 11

Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog® (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Xentria, Inc. | Recruiting ➔ Completed

Trial completion

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=255 | Active, not recruiting | Sponsor: Emory University | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison chart: Some available insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SPEED: Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Stanford University | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (clinicaltrials.gov) - P4 | N=76 | Completed | Sponsor: Medical University of Warsaw | Not yet recruiting ➔ Completed | Trial completion date: Aug 2023 ➔ Dec 2024

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog® (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Xentria, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

Autoimmune Gastroparesis and Immune Thrombocytopenia-Effective Treatment With Immunomodulation (ACG 2025) - "She developed symptoms of nausea and vomiting which occurred in the August of 2019 and resulted in hospitalization where she was noted to have severe thrombocytopenia 12 K. Work up yielded a diagnosis of ITP and was started on IVIg and Prednisone taper over 8 weeks with excellent response...She recalls her diagnosis of Type 2 Diabetes mellitus predated her diagnosis of ITP by 1 year and after weight loss of 60 lbs (199 lbs to 139 lbs ), her hemoglobin A1c normalized and she was taken off Humalog and Triseba for diabetes...Her ITP relapsed in Aug of 2023 with shorter duration of response to Dexamethasone and so was started on pulse dose Dexamethasone and Rituximab weekly for 4 doses in October 2023 and her ITP went into remission till October 2024 when a repeat course of Dexamethasone and Rituxamab was administered for recurrent thrombocytopenia with good response. In early 2025, she was hospitalized with refractory vomiting and was started on pulse dose Dexamethasone and..."

Immunomodulating • CNS Disorders • Depression • Diabetes • Gastrointestinal Disorder • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Metabolic Disorders • Migraine • Psychiatry • Thrombocytopenia • Thrombocytopenic Purpura • Type 2 Diabetes Mellitus

Neonatal Diabetes Mellitus with Maternal Pembrolizumab Exposure: A Complex Interplay of Genetic and Autoimmune Factors (AAP-NCE 2025) - "Subsequent management involved injections of diluted insulin (U10 Humalog), maintaining target glucose levels of 200–250 mg/dL. The presented case highlights the critical diagnostic considerations involving NDM, autoimmune mechanisms, and genetics. This case shows the challenges of diagnosis and management of NDM. Recognition of ICIs like Pembrolizumab as potential inducers, combined with genetic mutations such as LRBA, is essential for accurate diagnosis and effective intervention of neonatal autoimmune disorders. Early comprehensive genetic evaluation and personalized management strategies remain crucial for optimizing outcomes in affected neonates."

IO biomarker • Breast Cancer • Diabetes • Endocrine Disorders • Hypoglycemia • Immunology • Metabolic Disorders • Rare Diseases • Solid Tumor

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog® (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: Xentria, Inc.

New P1 trial

SPEED: Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Stanford University

New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Centre for Addiction and Mental Health | Trial completion date: Apr 2025 ➔ Apr 2026 | Trial primary completion date: Apr 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • CNS Disorders • Metabolic Disorders • Psychiatry • Schizophrenia

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Mark D. DeBoer, MD, MSc., MCR | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=260 | Recruiting | Sponsor: Emory University | Trial completion date: Jul 2025 ➔ May 2026 | Trial primary completion date: Jul 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders

Nano-Amounts of Glucagon Premixed With Fast-Acting Insulin Lispro: Effect on Insulin Absorption in Pigs. (PubMed, Curr Ther Res Clin Exp) - "Nine pigs were included in the control groups; they received a subcutaneous injection of 10 U of insulin lispro (LyumjevⓇ or HumalogⓇ). A similar trend was observed when HumalogⓇ/glucagon was injected (306 mU×min/L vs 65 mU×min/L, SE = 125), although this difference did not reach statistical significance (P = 0.102) compared with the control groups. This series of proof-of-concept experiments in anesthetized pigs indicate that premixing nanogram doses of glucagon in fast-acting insulin lispro formulations may speed up the absorption of subcutaneously injected insulin."

Journal • Anesthesia